A drug for autoimmune disease Sjögren's syndrome, picked up by Novartis when it bought MorphoSys for $2.9 billion last year, has hit the target in a pair of phase 3 trials. Ianalumab (VAY736), a drug ...
Raised in London and Accra, Baff Akoto is an artist working across multiple mediums. A self-taught filmmaker, Baff is interested in the fluidity of visual grammar and characters who wrestle with ...
Studies of mouse models of lupus provided the rationale for targeting BAFF in the treatment of patients with systemic lupus erythematosus, and could also help explain why individuals might differ in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results